(R)-6-Dimethylamino-2-(4-methoxy-benzenesulfonylamino)-hexanoic acid | 1027982-41-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-6-Dimethylamino-2-(4-methoxy-benzenesulfonylamino)-hexanoic acid
• 英文别名: (2R)-6-(dimethylamino)-2-[(4-methoxyphenyl)sulfonylamino]hexanoic acid
• CAS: 1027982-41-7
• 化学式: C₁₅H₂₄N₂O₅S
• 分子量: 344.432
• InChiKey: ARLIBKLVOJTRKQ-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (R)-6-Dimethylamino-2-(4-methoxy-benzenesulfonylamino)-hexanoic acid 在 N-甲基吗啉 、 盐酸 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 55.0h， 生成 N-(t-butyloxy)-2(R)-[[4-methoxybenzenesulfonyl](benzyl)amino]-6-(N,N-dimethylamino) hexanamide
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c
• 作为产物：
  描述：

  对甲氧基苯磺酰氯 、 (R)-2-Amino-6-dimethylamino-hexanoic acid 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 (R)-6-Dimethylamino-2-(4-methoxy-benzenesulfonylamino)-hexanoic acid
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c